stockrow
Friday 6 November 2026
Export NRC’s income statement to Excel — free account
National Research Corporation
NRC Healthcare Health Information Services
National Research Corporation’s revenue for fiscal 2025 (year ended December 2025) was $137.4 million, down 3.96% from fiscal 2024.
- Revenue
- +11.0%
- EPS
- +20.3%
- Free cash flow
- −31.4%
- Total debt
- +29.1%
Quarter to September 2026, against a year earlier
25.83
0.35
+1.37%
Follow NRC
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
37.15 | 42.95 | 86.28 | 73.96 |
P/S ratio |
3.06 | 2.67 | 3.39 | 3.20 | |
P/FCF ratio |
26.69 | 21.24 | 21.94 | 24.95 | |
P/Operating CF |
58.52 | 51.55 | 342.52 | 57.40 | |
P/B ratio |
30.03 | 27.43 | 72.49 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.57 | 3.19 | 3.98 | 3.86 | |
EV/EBITDA |
16.20 | 15.81 | 23.74 | 22.63 | |
EV/Operating CF |
18.56 | 16.37 | 18.89 | 23.35 | |
EV/FCF |
31.19 | 25.34 | 25.76 | 30.08 | |
Quick Ratio |
0.43 | 0.36 | 0.48 | 0.52 | |
Current Ratio |
0.55 | 0.52 | 0.65 | 0.64 | |
Net Debt/EBITDA |
10.36 | 9.20 | (75.86) | 8.59 | |
Debt/Assets |
55.62% | 55.01% | 63.17% | 70.49% | |
Debt/Equity |
5.36 | 5.48 | 13.13 | (10.76) | |
Asset Turnover |
1.03 | 1.03 | 1.01 | 1.05 | |
Operating CF/Net income |
4.82 | 2.23 | (0.42) | 1.70 | |
Capex/Depreciation |
(0.52) | (0.84) | (0.62) | (0.50) | |
Interest Coverage |
3.41 | 4.44 | (2.45) | 5.81 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
41.04% | 38.56% | 64.83% | 31.37% | |
Intangible Assets out of Total Assets |
0.51 | 0.51 | 0.50 | 0.49 | |
Share Based Compensation of Revenue |
5.42% | 4.62% | 20.83% | (0.35%) | |
Graham Net Nets |
(0.24) | (0.27) | (0.22) | (0.26) | |
Graham Number |
2.67 | 2.35 | 1.29 | 0.00 | |
Earnings Yield |
2.69% | 2.33% | 1.16% | 1.35% | |
Free Cash Flow Yield |
3.75% | 4.71% | 4.56% | 4.01% | |
Revenue per Share |
1.57 | 1.60 | 1.61 | 1.77 | |
Operating CF per Share |
0.32 | 0.33 | 0.06 | 0.37 | |
Capex per Share |
(0.05) | (0.08) | (0.06) | (0.05) | |
Free Cash Flow per Share |
0.27 | 0.25 | 0.00 | 0.32 | |
Cash per Share |
0.18 | 0.12 | 0.15 | 0.17 | |
Shareholders Equity per Share |
0.63 | 0.62 | 0.30 | (0.42) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.63 | 0.62 | 0.30 | (0.42) | |
Free Cash Flow |
6.06 | 5.35 | 0.06 | 6.98 | |
Working Capital |
(16.41) | (18.49) | (12.21) | (15.13) | |
Capital Expenditures |
(1.12) | (1.83) | (1.32) | (1.04) | |
Net Current Asset Value |
(100.68) | (101.08) | (106.80) | (121.62) | |
EV/EBIT |
21.74 | 22.57 | 37.82 | 34.88 | |
Capex to Sales |
0.03 | 0.05 | 0.04 | 0.03 | |
Price to Operating Income |
18.60 | 18.92 | 32.21 | 28.94 | |
| Other line items | |||||
Average Receivables |
11.42 | 11.39 | 13.25 | 15.51 | |
Average Payables |
1.18 | 2.13 | 1.25 | 1.26 | |
Average Assets |
133.71 | 134.87 | 138.77 | 137.47 | |
Average Common Equity |
22.64 | 21.58 | 13.94 | 2.60 |
Columns are period end dates · fundamentals updated 6 Nov 2026